WO2004042076A3 - Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine - Google Patents

Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine Download PDF

Info

Publication number
WO2004042076A3
WO2004042076A3 PCT/EP2003/011879 EP0311879W WO2004042076A3 WO 2004042076 A3 WO2004042076 A3 WO 2004042076A3 EP 0311879 W EP0311879 W EP 0311879W WO 2004042076 A3 WO2004042076 A3 WO 2004042076A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde4a
diseases
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2003/011879
Other languages
English (en)
Other versions
WO2004042076A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003274082A priority Critical patent/AU2003274082A1/en
Publication of WO2004042076A2 publication Critical patent/WO2004042076A2/fr
Publication of WO2004042076A3 publication Critical patent/WO2004042076A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une PDE4A humaine qui est associée aux troubles du système nerveux central et périphérique, aux maladies cardiovasculaires, aux maladies hématologiques, aux inflammations, aux maladies gastro-entérologiques et aux maladies endocrinologiques. L'invention concerne également des dosages permettant d'identifier des composés utiles pour le traitement et la prévention des troubles du système nerveux central et périphérique, des maladies cardiovasculaires, des maladies hématologiques, des maladies gastro-entérologiques et des maladies endocrinologiques. L'invention se rapporte enfin à des composés qui se lient à PDE4A et/ou activent ou inhibent l'activité de PDE4A, et à des compositions pharmaceutiques renfermant lesdits composés.
PCT/EP2003/011879 2002-11-08 2003-10-25 Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine WO2004042076A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274082A AU2003274082A1 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024994.2 2002-11-08
EP02024994 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004042076A2 WO2004042076A2 (fr) 2004-05-21
WO2004042076A3 true WO2004042076A3 (fr) 2004-10-14

Family

ID=32309318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011879 WO2004042076A2 (fr) 2002-11-08 2003-10-25 Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine

Country Status (2)

Country Link
AU (1) AU2003274082A1 (fr)
WO (1) WO2004042076A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977305A (en) * 1990-04-20 1999-11-02 Cold Spring Harbor Laboratories Cloning by complementation and related processes
WO2000040714A2 (fr) * 1998-12-30 2000-07-13 Oligos Etc. Inc. Inhibiteurs de la phosphodiesterase utilises a des fins therapeutiques
US6100025A (en) * 1990-04-20 2000-08-08 Cold Spring Harbor Laboratory Cloning by complementation and related processes
WO2001079526A2 (fr) * 2000-04-17 2001-10-25 Bioimage A/S Procede faisant appel a des cellules vivantes pour identifier des composes modulant la distribution intracellulaire de phosphodiesterases (pde)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977305A (en) * 1990-04-20 1999-11-02 Cold Spring Harbor Laboratories Cloning by complementation and related processes
US6100025A (en) * 1990-04-20 2000-08-08 Cold Spring Harbor Laboratory Cloning by complementation and related processes
WO2000040714A2 (fr) * 1998-12-30 2000-07-13 Oligos Etc. Inc. Inhibiteurs de la phosphodiesterase utilises a des fins therapeutiques
WO2001079526A2 (fr) * 2000-04-17 2001-10-25 Bioimage A/S Procede faisant appel a des cellules vivantes pour identifier des composes modulant la distribution intracellulaire de phosphodiesterases (pde)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOLGER G B: "THE MULTIENZYME PDE4 CYCLIC ADENOSINE MONOPHOSPHATE-SPECIFIC PHOSPHODIESTERASE FAMILY: INTRACELLULAR TARGETING, REGULATION, AND SELECTIVE INHIBITION BY COMPOUNDS EXERTING ANTI-INFLAMMATORY AND ANTIDEPRESSANT ACTIONS", ADVANCES IN PHARMACOLOGY, SAN DIEGO, CA, US, vol. 44, 1998, pages 225 - 342, XP000906963 *
DATABASE EBI EMBL; COLICELLI ET AL.: "pPDE46", XP002280028, retrieved from EBI Database accession no. AAY49804 *
DATABASE EBI EMBL; COLICELLI ET AL.: "pPDE4A", XP002280027, retrieved from EBI Database accession no. AAB20639 *
DATABASE EBI EMBL; DALE ET AL.: "human phosphodiesterase isoform", XP002280279, retrieved from EBI Database accession no. AAY93992 *
DATABASE EBI EMBL; TERRY ET AL.: "HSPDE4A4-EGFP", XP002280278, retrieved from EBI Database accession no. AAG65779 *
DINTER H ET AL: "Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 75, no. 2, February 1997 (1997-02-01), pages 95 - 102, XP002113590 *
DYKE H J ET AL: "THE THERAPEUTIC POTENTIAL OF PDE4 INHIBITORS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 8, no. 9, 1999, pages 1301 - 1325, XP001096074 *
DYKE H J ET AL: "UPDATE ON THE THERAPEUTIC POTENTIAL OF PDE4 INHIBITORS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 1, no. 11, January 2002 (2002-01-01), pages 1 - 13, XP008002007 *
TAKAHASHI MICHIHIRO ET AL: "Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 610 - 618, XP002275242 *

Also Published As

Publication number Publication date
WO2004042076A2 (fr) 2004-05-21
AU2003274082A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2003065044A8 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2004042076A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2004071394A3 (fr) Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
WO2004042077A3 (fr) Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2004042405A3 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2004015427A3 (fr) Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2004015422A3 (fr) Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire
WO2004038406A3 (fr) Diagnostic et therapie de maladies associees au recepteur 42 couple a la proteine g (gpr42) humain
WO2004050903A3 (fr) Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP